Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom
- 3 December 2013
- journal article
- Published by Springer Nature in Osteoporosis International
- Vol. 25 (4) , 1275-1283
Abstract
The incidence of clinical fractures and the associated factors were assessed in patients with systemic lupus erythematosus (SLE) versus matched controls. We found an increased fracture risk in SLE patients compared to controls. Glucocorticoid use, longer disease duration, neuropsychiatric disease complications and previous osteoporotic fractures were identified as associated factors. The aims of this study were to estimate the risk of clinical fractures in patients with SLE versus matched controls and to evaluate the risk factors associated with clinical fractures in SLE. This is a population-based cohort study using the Clinical Practice Research Datalink (from 1987–2012). Each SLE patient (n = 4,343) was matched with up to six controls (n = 21,780) by age and sex. Clinical fracture type was stratified according to the WHO definitions into osteoporotic and non-osteoporotic fracture. Cox proportional hazards calculated relative rates (RR) of clinical fracture and time interaction terms to evaluate the timing patterns of fracture. Clinical fracture rates in SLE patients, stratified by age, gender, type of fracture, disease duration and therapy variables, were compared with those rates in controls. Follow-up durations were 6.4 years in SLE patients and 6.6 years in controls. SLE patients had a 1.2-fold increased clinical fracture risk compared to controls (adjusted RR = 1.22, 95% CI = 1.05–1.42), and the risk further increased with a longer disease duration. Glucocorticoid (GC) use in the previous 6 months raised the risk of clinical fracture (adjusted RR = 1.27, 95% CI = 1.02–1.58). Cerebrovascular events, seizures and previous osteoporotic fractures were identified as predictors of clinical fractures. We found an increased risk of clinical fracture in SLE patients compared to controls. GC use in the previous 6 months and longer disease duration are associated with the increased fracture risk in SLE. Patients with neuropsychiatric organ damage or previous osteoporotic fractures are also at increased risk of the occurrence of clinical fractures.Keywords
This publication has 37 references indexed in Scilit:
- Osteoporosis and fractures in systemic lupus erythematosusArthritis Care & Research, 2011
- Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fracturesOsteoporosis International, 2011
- Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus.2008
- Self-reported fractures and associated factors in women with systemic lupus erythematosus.2007
- Use of beta‐2 agonists and risk of hip/femur fracture: a population‐based case‐control studyPharmacoepidemiology and Drug Safety, 2006
- BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosusRheumatology, 2005
- Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosusLupus, 2005
- The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and resultsPharmacoepidemiology and Drug Safety, 2000
- Use of Oral Corticosteroids and Risk of FracturesJournal of Bone and Mineral Research, 2000
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996